G Grassi

Summary

Affiliation: University of Milano-Bicocca
Country: Italy

Publications

  1. ncbi Multiple sampling improves norepinephrine reproducibility in essential hypertension: a comparison with the microneurographic technique
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Italy
    J Hypertens 26:2185-90. 2008
  2. ncbi Role of ambulatory blood pressure monitoring in resistant hypertension
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Via Pergolesi, 33, 20052, Monza, Milan, Italy
    Curr Hypertens Rep 15:232-7. 2013
  3. ncbi Structural alterations of the retinal microcirculation in the "prehypertensive" high- normal blood pressure state
    Guido Grassi
    Clinica Medica, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, 20052 Monza, Italy
    Curr Pharm Des 19:2375-81. 2013
  4. ncbi The clinical significance of blood pressure lowering treatment: is first-line drug choice important? : the contrary position
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo, Monza, University of Milan Bicocca, Via Pergolesi 33, 20052, Milan, Italy
    High Blood Press Cardiovasc Prev 15:117-9. 2008
  5. ncbi Renal denervation in cardiometabolic disease: Concepts, achievements and perspectives
    G Grassi
    Clinica Medica, Department of Clinical Medicine and Prevention, University of Milano Bicocca, Milan, Italy Istituto di Ricerca e Cura a Carattere Scientifico Multimedica, Sesto San Giovanni, Milan, Italy Electronic address
    Nutr Metab Cardiovasc Dis 23:77-83. 2013
  6. ncbi Evaluation of the ASPIRANT trial Evaluation of Vàclavìk J, Sedlàk R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT). A randomized, double-blind, placebo-controlled trial. Hypertension 2011;29:600-60
    Guido Grassi
    University of Milano Bicocca and Istituto di Ricerca e Cura a Carattere Scientifico Multimedica, Clinica Medica, Sesto San Giovanni, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, 20052 Monza Milan, Italy 39 039 233 357 39 039 322 274
    Expert Opin Pharmacother 13:2573-7. 2012
  7. ncbi Novel antihypertensive therapies: renal sympathetic nerve ablation and carotid baroreceptor stimulation
    Guido Grassi
    Clinica Medica, Department of Clinical Medicine and Prevention, University of Milano Bicocca, Monza, MI, Italy
    Curr Hypertens Rep 14:567-72. 2012
  8. ncbi Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo dei Tintori Monza, University of Milano Bicocca, Milan, Italy
    Curr Hypertens Rep 14:333-8. 2012
  9. ncbi The sympathetic nervous system and new nonpharmacologic approaches to treating hypertension: a focus on renal denervation
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Milan, Italy
    Can J Cardiol 28:311-7. 2012
  10. ncbi Blood pressure control and antihypertensive treatment
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo dei Tintori Monza, University of Milano Bicocca, Milan, Italy
    Curr Vasc Pharmacol 10:506-11. 2012

Collaborators

Detail Information

Publications123 found, 100 shown here

  1. ncbi Multiple sampling improves norepinephrine reproducibility in essential hypertension: a comparison with the microneurographic technique
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Italy
    J Hypertens 26:2185-90. 2008
    ..This was done by taking muscle sympathetic nerve traffic recording as 'gold standard', which is characterized by an elevated short- and long-term reproducibility...
  2. ncbi Role of ambulatory blood pressure monitoring in resistant hypertension
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Via Pergolesi, 33, 20052, Monza, Milan, Italy
    Curr Hypertens Rep 15:232-7. 2013
    ..The present paper will critically review the main features of ambulatory blood pressure monitoring in resistant hypertension, with particular emphasis on the diagnosis and treatment of this high-risk hypertensive state...
  3. ncbi Structural alterations of the retinal microcirculation in the "prehypertensive" high- normal blood pressure state
    Guido Grassi
    Clinica Medica, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, 20052 Monza, Italy
    Curr Pharm Des 19:2375-81. 2013
    ..The possible hemodynamic and non-hemodynamic mechanisms resposible for these structural alteations of the retinal microcirculation will be also discussed...
  4. ncbi The clinical significance of blood pressure lowering treatment: is first-line drug choice important? : the contrary position
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo, Monza, University of Milan Bicocca, Via Pergolesi 33, 20052, Milan, Italy
    High Blood Press Cardiovasc Prev 15:117-9. 2008
    ..The difference between drugs will become increasingly important as the cardiovascular risk profile of the patient becomes elevated and/or when associated risk factors or concomitant target organ damage are detected...
  5. ncbi Renal denervation in cardiometabolic disease: Concepts, achievements and perspectives
    G Grassi
    Clinica Medica, Department of Clinical Medicine and Prevention, University of Milano Bicocca, Milan, Italy Istituto di Ricerca e Cura a Carattere Scientifico Multimedica, Sesto San Giovanni, Milan, Italy Electronic address
    Nutr Metab Cardiovasc Dis 23:77-83. 2013
    ..e. insulin resistance, glucose intolerance, and diabetes mellitus) frequently detectable in resistant hypertensive patients. The present viewpoint article critically examines the results obtained so far in this area...
  6. ncbi Evaluation of the ASPIRANT trial Evaluation of Vàclavìk J, Sedlàk R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT). A randomized, double-blind, placebo-controlled trial. Hypertension 2011;29:600-60
    Guido Grassi
    University of Milano Bicocca and Istituto di Ricerca e Cura a Carattere Scientifico Multimedica, Clinica Medica, Sesto San Giovanni, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, 20052 Monza Milan, Italy 39 039 233 357 39 039 322 274
    Expert Opin Pharmacother 13:2573-7. 2012
    ..4/1.0 mmHg. Although a number of limitations weaken some of the study conclusions, ASPIRANT trial provides the first controlled evidence on the blood pressure-lowering effects of low-dose spironolactone in resistant hypertensive patients...
  7. ncbi Novel antihypertensive therapies: renal sympathetic nerve ablation and carotid baroreceptor stimulation
    Guido Grassi
    Clinica Medica, Department of Clinical Medicine and Prevention, University of Milano Bicocca, Monza, MI, Italy
    Curr Hypertens Rep 14:567-72. 2012
    ..This paper will provide a comparison of the effects of the two procedures, highlighting their effects on blood pressure, metabolic profile, target organ damage, safety and tolerability profile...
  8. ncbi Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo dei Tintori Monza, University of Milano Bicocca, Milan, Italy
    Curr Hypertens Rep 14:333-8. 2012
    ..This review will discuss the evidence collected over the past few years on the relationships between sympathetic activation and blood pressure variability and their impact on cardiovascular risk profile...
  9. ncbi The sympathetic nervous system and new nonpharmacologic approaches to treating hypertension: a focus on renal denervation
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Milan, Italy
    Can J Cardiol 28:311-7. 2012
    ..Strengths and potential limitations of the renal denervation approach are briefly addressed...
  10. ncbi Blood pressure control and antihypertensive treatment
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo dei Tintori Monza, University of Milano Bicocca, Milan, Italy
    Curr Vasc Pharmacol 10:506-11. 2012
    ..The possible approaches for controlling elevated BP values will be highlighted...
  11. ncbi New therapeutic approaches for resistant hypertension
    Guido Grassi
    Department of Internal Medicine, S Gerardo Hospital, Monza, University of Milano Bicocca, Milan, Italy
    J Nephrol 25:276-81. 2012
    ..The pros and cons of each intervention as well as the questions that remain to be addressed in the future will also be discussed...
  12. ncbi The TALENT Study
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo, Via Pergolesi 33, 20052 Monza Milano, Italy
    Expert Opin Pharmacother 13:607-11. 2012
    ....
  13. ncbi Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension
    Guido Grassi
    Department of Internal Medicine and Cardiovascular Prevention, S Gerardo Hospital, University of Milano Bicocca, Monza, Milan, Italy
    J Renin Angiotensin Aldosterone Syst 9:66-74. 2008
    ....
  14. ncbi Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives
    Guido Grassi
    Dipartimento di Medicina Clinica, Clinica Medica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Italy
    Hypertension 52:925-31. 2008
    ..The present data suggest that in hypertension, sympathetic activation represents a mechanism potentially responsible for the day-night blood pressure difference...
  15. ncbi Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza Milan, Italy
    Eur J Heart Fail 10:1186-91. 2008
    ....
  16. ncbi Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica e Prevenzione, Universita Milano Bicocca, Ospedale San Gerardo di Tintori Monza, Milan, Italy
    Curr Vasc Pharmacol 7:137-45. 2009
    ....
  17. ncbi Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Milan, Italy
    Hypertension 53:205-9. 2009
    ..The sympathetic overactivity, which is likely to be related to the baroreflex impairment, may account for the increased cardiovascular risk characterizing diastolic dysfunction...
  18. ncbi Reproducibility patterns of plasma norepinephrine and muscle sympathetic nerve traffic in human obesity
    G Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, 20052 Monza Milano, Italy
    Nutr Metab Cardiovasc Dis 19:469-75. 2009
    ....
  19. ncbi Behaviour of regional adrenergic outflow in mild-to-moderate renal failure
    Guido Grassi
    Dipartimento di Medicina Clinica e Prevenzione, Universita Milano Bicocca, Clinica Medica, Ospedale San Gerardo, Monza, Italy
    J Hypertens 27:562-6. 2009
    ..No information exists, however, as to whether the adrenergic overdrive is confined to selected vascular districts or is rather generalized to the whole cardiovascular system...
  20. ncbi Essential hypertension and the sympathetic nervous system
    Guido Grassi
    Clinica Medica, Università Milano Bicocca Ospedale San Gerardo, Via Pergolesi 33, 20052 Monza, Milan, Italy
    Neurol Sci 29:S33-6. 2008
    ..Finally the therapeutic implications of hypertension-related neurogenic abnormalities will be highlighted...
  21. ncbi Blood pressure lowering effects of rimonabant in obesity-related hypertension
    G Grassi
    Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Milan, Italy
    J Neuroendocrinol 20:63-8. 2008
    ..These effects, which appear to be triggered by the weight reduction induced by the drug, are clinically relevant because they contribute favourably to lower the elevated cardiovascular risk profile of the obese hypertensive patient...
  22. ncbi Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Milan, Italy
    Hypertension 49:535-41. 2007
    ..Thus, obesity and metabolic syndrome potentiate the sympathetic activation characterizing heart failure. This potentiation is likely to mainly depend on metabolic and baroreflex mechanisms...
  23. ncbi Blood pressure lowering effects of non-surgical procedures for vascular decompression: good news to be taken with caution
    G Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Ospedale San Gerardo, Monza (Milan, Italy
    J Hum Hypertens 21:341-2. 2007
  24. ncbi Sympathetic overdrive and cardiovascular risk in the metabolic syndrome
    Guido Grassi
    Istituto di Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Milan, Italy
    Hypertens Res 29:839-47. 2006
    ....
  25. ncbi Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Milan, Italy
    Blood Press 15:268-74. 2006
    ....
  26. ncbi Cardiovascular risk and adrenergic overdrive in the metabolic syndrome
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo dei Tintori, Via Pergolesi 33, 20052 Monza, Milan, Italy
    Nutr Metab Cardiovasc Dis 17:473-81. 2007
    ..This paper will review the role of the sympathetic nervous system in the pathogenesis of the metabolic syndrome as well as its importance as target of non-pharmacologic and pharmacologic treatment...
  27. ncbi Blood pressure control and therapeutic modulation of the adrenergic overdrive
    Guido Grassi
    Clinica Medica, , Ospedale San Gerardo, Via Pergolesi 33, 20052 Monza (Milan, Italy
    Curr Hypertens Rep 9:167-9. 2007
  28. ncbi Neurogenic abnormalities in masked hypertension
    Guido Grassi
    Clinica Medica, Universita Milano Bicocca, Ospedale S Gerardo, Monza, Italy
    Hypertension 50:537-42. 2007
    ..46; P<0.01). These data provide the first evidence that masked hypertension is characterized by a marked sympathetic overdrive. They further show that the neurogenic alterations are coupled with metabolic and baroreflex abnormalities...
  29. ncbi Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials
    Guido Grassi
    Clinica Medica, Ospedale S Gerardo, Universita Milano Bicocca, Via Pergolesi 33, 20052, Monza Milan, Italy
    Curr Hypertens Rep 9:299-304. 2007
    ....
  30. ncbi Heart rate as a sympathetic marker during acute adrenergic challenge
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Milan, Italy
    J Hypertens 26:70-5. 2008
    ..Whether this also applies to the ability of heart rate to reflect acute and generalized changes in sympathetic activity is unknown...
  31. ncbi Sympathetic activation in cardiovascular and renal disease
    Guido Grassi
    Department of Clinical Medicine, Prevention and Health Biotechnology, University of Milan Bicocca, San Gerardo Hospital, Monza, Milan, Italy
    J Nephrol 22:190-5. 2009
    ..This has therapeutic implications, which involve the need to use treatments that oppose rather than enhance sympathetic neural activation...
  32. ncbi Implementation of new evidence into hypertension guidelines: the case of the ONTARGET and TRANSCEND trials
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica e Prevenzione, Ospedale S Gerardo Monza, Universita Milano Bicocca, Italy bInstituto Auxologico Italiano, Milan, Italy
    J Hypertens Suppl 27:S40-4. 2009
    ..This review article examines in depth the results of the two above-mentioned trials as well as their impact on guidelines on antihypertensive treatment...
  33. ncbi Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica e Prevenzione, Universita Milano Bicocca, Ospedale San Gerardo, 20052 Monza Milan, Italy
    Metabolism 58:1446-51. 2009
    ..This may depend on the fact that muscle and skin sympathetic nerve activities are regulated by mechanisms that are affected in a different fashion by the various components of the disease...
  34. ncbi Selective endothelin receptor blockade in resistant hypertension: results of the DORADO trial
    Guido Grassi
    University of Milano Bicocca, Clinica Medica, Ospedale San Gerardo, Via Pergolesi 33, 20052 Monza Milano, Italy 39 039 233 3357 39 039 322 274
    Expert Opin Pharmacother 12:153-5. 2011
    ..Although these data are promising, the drug requires further evaluation, with particularly regard to the long term...
  35. ncbi Blood pressure control in resistant hypertension: new therapeutic options
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Via Pergolesi 33, 20052 Monza, Milan, Italy
    Expert Rev Cardiovasc Ther 8:1579-85. 2010
    ..Clinical studies and large-scale clinical trials are presently ongoing with the aim of defining the long-term efficacy and safety profile of the two interventions...
  36. ncbi Cardiovascular consequences of poor compliance to antihypertensive therapy
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza Milan, Italy
    Blood Press 20:196-203. 2011
    ..This could have implications for CV protection, as confirmed by the results of recent clinical trials. Thus, ARBs should be considered as an alternative to angiotensin-converting enzyme inhibitors in patients at risk of low adherence...
  37. ncbi Early sympathetic activation in the initial clinical stages of chronic renal failure
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica e Prevenzione, Universita Milano Bicocca, Ospedale San Gerardo, Via Pergolesi 33, 20052 Monza, Italy
    Hypertension 57:846-51. 2011
    ..The sympathetic overdrive parallels the severity of the renal failure, state and, thus, it might participate, in conjunction with other factors, at the disease progression...
  38. ncbi Sympathetic mechanisms, organ damage, and antihypertensive treatment
    Guido Grassi
    Clinica Medica, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, 20052 Monza, Milan, Italy
    Curr Hypertens Rep 13:303-8. 2011
    ..This paper reviews evidence collected over the past few years documenting the importance of neurogenic factors in the development and progression of end-organ damage. The therapeutic implications of this evidence are also highlighted...
  39. ncbi The ACQUIRE trial
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica e Prevenzione, Ospedale San Gerardo, Universita Milano Bicocca, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, 20052 Monza Milan, Italy
    Expert Opin Pharmacother 12:1665-7. 2011
    ..The combination drug regimen, which can achieve early blood pressure control, was accompanied by an excellent side-effect and safety profile and thus was associated with a high adherence to treatment...
  40. ncbi The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
    Guido Grassi
    Dipartimento di Medicina Clinica e Prevenzione, Ospedale San Gerardo dei Tintori Monza, Universita Milano Bicocca, Milan, Italy
    Expert Opin Pharmacother 12:2421-4. 2011
    ..Despite the nephroprotective properties of olmesartan, the drug did not reduce the number of cardiovascular events and cardiovascular complications associated with the diabetic state...
  41. ncbi Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo, Monza Milan, Department of Prevention and Clinical Medicine, University of Milano Bicocca, Milan, Italy
    Clin J Am Soc Nephrol 6:2620-7. 2011
    ..Sympathetic overactivity and high levels of the endogenous inhibitor of NO synthase asymmetric dimethylarginine (ADMA) are prevalent risk factors in chronic kidney disease (CKD)...
  42. ncbi Sympathetic neural activity in hypertension and related diseases
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo dei Tintori, Universita Milano Bicocca, Italy
    Am J Hypertens 23:1052-60. 2010
    ..This has led many years ago investigators to advance the hypothesis that alterations in the sympathetic modulation of the cardiovascular system may occur in hypertension and related disease...
  43. ncbi The "J curve" problem revisited: old and new findings
    Guido Grassi
    Clinica Medica, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, 20052, Monza, Milan, Italy
    Curr Hypertens Rep 12:290-5. 2010
    ....
  44. ncbi Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Milan, Italy
    Obesity (Silver Spring) 18:92-8. 2010
    ....
  45. ncbi Antihypertensive treatment and stroke prevention: from recent meta-analyses to the PRoFESS trial
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo, Via Pergolesi 33, 20052 Monza Milan, Italy
    Curr Hypertens Rep 11:265-70. 2009
    ....
  46. ncbi Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica e Prevenzione, Universita di Milano Bicocca, Ospedale San Gerardo, Milan, Italy
    Prog Cardiovasc Dis 52:31-7. 2009
    ..Taken together, these findings reinforce the concept that drugs used in the metabolic syndrome should exert sympathoinhibitory effects...
  47. ncbi Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives
    Guido Grassi
    Clinica Medica, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, Monza, Italy
    Hypertension 54:690-7. 2009
    ..Finally, the clinical and therapeutic implications of the neuroadrenergic abnormalities occurring in hypertension, as well as the areas worthy of future research, will be highlighted...
  48. ncbi Prevalence of cardiovascular risk factors in an unselected italian population. Results of the Cardiolab Project 2004-2008
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Milan
    Acta Cardiol 64:771-8. 2009
    ..The CardioLab project is an observational cross-sectional study aimed at determining the prevalence of CV risk factors in a large unselected sample of the Italian population leaving in northern, central and southern Italy...
  49. ncbi Reinforcement of the adrenergic overdrive in the metabolic syndrome complicated by obstructive sleep apnea
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Italy
    J Hypertens 28:1313-20. 2010
    ....
  50. ncbi Diurnal blood pressure variation and sympathetic activity
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo, Universita Milano Bicocca, Monza, Italy
    Hypertens Res 33:381-5. 2010
    ..Finally, this paper examines altered neuroadrenergic influences on nocturnal blood pressure reduction and blood pressure variability...
  51. ncbi Impact of the metabolic syndrome on subcutaneous microcirculation in obese patients
    Guido Grassi
    Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Clinica Medica, Monza, Italy
    J Hypertens 28:1708-14. 2010
    ..It is also unknown whether and to what extent the hypothesized microvascular alterations are greater for magnitude than the ones characterizing obesity, that is the most common component of the metabolic syndrome...
  52. ncbi The 'neuroadrenergic hypothesis' in hypertension: current evidence
    Guido Grassi
    Clinica Medica, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, 20052 Monza, Milan, Italy
    Exp Physiol 95:581-6. 2010
    ..Finally, the new frontiers of research in the area of therapeutic intervention aimed at reducing the adrenergic overdrive will be highlighted...
  53. ncbi Sympathetic drive as a determinant of weight loss intervention outcome strengths and limitations
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Ospedale San Gerardo, Monza, Milan, Italy
    Am J Hypertens 18:1517-8. 2005
  54. ncbi Hypertension, antihypertensive treatment and stroke prevention
    G Grassi
    Clinica Medica, Ospedale S Gerardo dei Tintori, Via Donizetti 106, I 20052 Monza MI, Italy
    Neurol Sci 26:S22-3. 2005
    ....
  55. ncbi Aging, physical fitness and endothelial function: are all ultracentenarians marathon runners?
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Centro Interuniversitario di Fisiologia Clinica e Ipertensione and Centro Auxologico Italiano, Milano, Italy
    Clin Sci (Lond) 106:239-40. 2004
    ..The main features of the study as well as its potential limitations will be also highlighted...
  56. ncbi Sympathetic and baroreflex function in hypertension: implications for current and new drugs
    Guido Grassi
    Clinica Medica, Dipartimento Universitario di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Via Donizetti 106, 20052 Monza Milano, Italy
    Curr Pharm Des 10:3579-89. 2004
    ..The rationale for obtaining during antihypertensive drug treatment an effective sympathoinhibition will be finally highlighted...
  57. ncbi Intermediate versus hard end points in clinical trials on hypertension
    Guido Grassi
    Clinica Medica, Ospedale S Gerardo, Via Donizetti 106, 20052 Monza Milano, Italy
    Curr Hypertens Rep 7:294-7. 2005
    ..The advantages, limitations, and clinical relevance of each approach are highlighted...
  58. ncbi Leptin, sympathetic nervous system, and baroreflex function
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo, Via Donizetti 106, 20052, Monza Milano, Italy
    Curr Hypertens Rep 6:236-40. 2004
    ....
  59. ncbi Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: rationale and options
    Guido Grassi
    Clinica Medica, , Via Donizetti 106, 20052 Monza (MI, Italy
    Curr Hypertens Rep 5:277-80. 2003
  60. ncbi Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population
    Guido Grassi
    Clinica Medica, Ospedale San Gerardo, Monza, Italy
    J Hypertens 29:1121-7. 2011
    ..We followed this with functional studies to elucidate a possible mechanism for the top association signal...
  61. ncbi Reviewer critique of the sympathetic drive after acute myocardial infarction in hypertensive patients
    Guido Grassi
    Istituto di Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Ospedale San Gerardo, Monza (Milan, Italy
    Am J Hypertens 19:1077-8. 2006
  62. ncbi Metabolic syndrome and cardiometabolic risk: an update
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo dei Tintori, Monza Milan, Italy
    Blood Press 18:7-16. 2009
    ..The general therapeutic recommendations, provided by the 2007 European Society of Hypertension/European Society of Cardiology Guidelines, will be briefly discussed...
  63. ncbi Baroreflex function in hypertension: consequences for antihypertensive therapy
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Ospedale San Gerardo dei Tintori, Universita Milano Bicocca, Via Pergolesi 33, 20052 Monza, Milan, Italy
    Prog Cardiovasc Dis 48:407-15. 2006
    ..This review will examine the main features of cardiovascular reflex control in hypertension and the effects of the different classes of antihypertensive drugs in uncomplicated and complicated hypertension...
  64. ncbi Sympathetic nervous system: role in hypertension and in chronic kidney disease
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza Milan, Italy
    Curr Opin Nephrol Hypertens 21:46-51. 2012
    ..It also reviews the participation of sympathetic neural factors in the development of the earlier stages of renal failure...
  65. ncbi Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy
    G Grassi
    Clinica Medica, University of Milano-Bicocca, Ospedale San Gerardo dei Tintori, Via Donizetti 106, 20052 Monza-Milan, Italy
    Clin Sci (Lond) 101:141-6. 2001
    ..Thus the neuroadrenergic and reflex abnormalities characterizing CHF are independent of its aetiology...
  66. ncbi Mortality within the first 10 years of the disease in type 2 diabetic patients
    S Bo
    Department of Internal Medicine, University of Torino, Corso Dogliotti 14, 10126 Torino, Italy
    Nutr Metab Cardiovasc Dis 16:8-12. 2006
    ..The aim of this study was to evaluate pattern and predictors of mortality after a 4.5 year follow-up in a cohort of type 2 diabetic patients, according to diabetes duration...
  67. ncbi Renal damage in patients with Type 2 diabetes: a strong predictor of mortality
    S Bo
    Department of Internal Medicine, University of Torino, Turin, Italy
    Diabet Med 22:258-65. 2005
    ....
  68. ncbi Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome
    G Grassi
    Department of Internal Medicine, Prevention and Medicine Biotechnologies, University Milano-Bicocca, Milan, Italy
    Diabetologia 48:1359-65. 2005
    ....
  69. ncbi A randomised controlled clinical trial of nurse-, dietitian- and pedagogist-led Group Care for the management of Type 2 diabetes
    M Trento
    Laboratory of Clinical Pedagogy, Department of Internal Medicine, University of Turin, Turin, Italy
    J Endocrinol Invest 31:1038-42. 2008
    ....
  70. ncbi Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure
    G Grassi
    Clinica Medica, , Ospedale San Gerardo, Monza (Milan, Italy
    Hypertension 38:286-91. 2001
    ..Whether this leads to further therapeutic benefits remains to be tested...
  71. ncbi Sympathoexcitatory responses to the acute blood pressure fall induced by central or peripheral antihypertensive drugs
    G Grassi
    Cattedra di Medicina Interna I, , Ospedale S. Gerardo dei Tintori, Monza, Italy
    Am J Hypertens 13:29-34. 2000
    ....
  72. ncbi Protective effects of renin-angiotensin blockade beyond blood pressure control
    G Mancia
    Clinica Medica, Dipartimento di Medicina Clinica e Prevenzione, Universita di Milano Bicocca, Ospedale San Gerardo, Milan, Italy
    J Hum Hypertens 23:570-7. 2009
    ..Conclusive demonstration that these blood pressure-independent effects do exist will require, however, a much more accurate and extended assessment of the blood pressure effects of the drugs...
  73. ncbi Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni
    Giuseppe Mancia
    Clinica Medica e Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie, , Ospedale San Gerardo, Monza Milano, Italy
    Hypertension 39:744-9. 2002
    ..They also imply that even effective treatment of hypertension does not allow complete reversal of the cardiac organ damage characterizing high BP states...
  74. ncbi Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Italy
    J Hypertens 22:1747-53. 2004
    ..This role, however, appears to be more pronounced in heart failure than in hypertension, in which the impaired vagal function may exert a concomitant favouring effect...
  75. ncbi Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Milano, Italy
    J Hypertens 22:2363-9. 2004
    ..This appears not to be related to gender or to baroreflex mechanisms but rather to metabolic factors, i.e. to the greater insulin resistance characterizing CO...
  76. ncbi Participation of the hypothalamus-hypophysis axis in the sympathetic activation of human obesity
    G Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Ospedale San Gerardo, Monza (Milan, Italy
    Hypertension 38:1316-20. 2001
    ..This suggests that hypothalamic and hypophyseal factors substantially contribute to the sympathoexcitation of obesity...
  77. ncbi Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Monza, Italy
    J Hypertens 21:1761-9. 2003
    ..Unlike diuretic treatment, however, treatment with candesartan cilexetil improves insulin sensitivity and exerts sympathoinhibitory effects...
  78. ncbi Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension
    Guido Grassi
    Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Monza, Milano, Italy
    Hypertension 41:558-62. 2003
    ..The acute sympathoexcitation, but not the small between-drugs differential chronic adrenergic effect, is accounted for by baroreflex impairment...
  79. ncbi Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis
    M Pozzi
    Cattedra di Medicina Interna, Universita degli Studi di Milano Bicocca, Divisione di Medicina 1, Milano, Italy
    Hepatology 34:1113-8. 2001
    ..The role of drugs modulating sympathoactivation should be investigated in preascitic cirrhosis...
  80. ncbi Treatment of heart failure with fosinopril: an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion
    G Mancia
    Cattedra di Medicina Interna, Ospedale S. Gerardo, Monza, , Italy
    Am J Hypertens 10:236S-241S. 1997
    ..CHF is accompanied with a decline or some sort of effect on renal function. An ACE inhibitor with a dual route of excretion, such as fosinopril, may be especially useful in treating patients with CHF...
  81. ncbi Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study
    Roberto Sega
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Ospedale San Gerardo, Monza, Italy
    Circulation 111:1777-83. 2005
    ..Systolic BP was almost invariably superior to diastolic BP, and night BP was superior to day BP...
  82. ncbi Impairment of thermoregulatory control of skin sympathetic nerve traffic in the elderly
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotechnologie Sanitarie, , Centro Interuniversitario di Fisiologia Clinica e Ipertensione and Istitutoto Auxologico Italiano, Italy
    Circulation 108:729-35. 2003
    ..They also show that aging markedly impairs thermoregulatory control of SSNA and that this impairment might participate at the age-related SSNA decrease...
  83. ncbi Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values
    Michele Bombelli
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza Milan, Italy
    J Hypertens 27:2458-64. 2009
    ....
  84. ncbi Short- and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Centro Interuniversitario di Fisiologia Clinica e Ipertensione and Istituto Auxologico Italiano, Milan, Italy
    Circulation 106:1957-61. 2002
    ..CONCLUSIONS: Thus, a moderate dietary sodium restriction triggers a sympathetic activation and a baroreflex impairment. Maintenance of low-sodium diet for several weeks does not attenuate these adverse adrenergic and reflex effects...
  85. ncbi Sympathetic response to ventricular extrasystolic beats in hypertension and heart failure
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Ospedale San Gerardo, Monza, Milan, Italy
    Hypertension 39:886-91. 2002
    ..This may represent an important factor for the genesis of the life-threatening ventricular arrhythmias that characterize CHF...
  86. ncbi Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis
    Massimo Pozzi
    Clinica Medica, Universita Milano Bicocca, Dipartimento di Radiologia, Ospedale San Gerardo, Monza, Italy
    Am J Gastroenterol 100:1110-6. 2005
    ....
  87. ncbi Effects of hypertension and obesity on the sympathetic activation of heart failure patients
    Guido Grassi
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Centro Interuniversitario di Fisiologia Clinica e Ipertensione and Istituto Auxologico Italiano, Milan, Italy
    Hypertension 42:873-7. 2003
    ....
  88. ncbi Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias
    Guido Grassi
    Istituto di Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, , Milan, Italy
    Acta Physiol Scand 177:399-404. 2003
    ..Finally, the sympathetic adjustments to spontaneously occurring or artificially induced pre-mature ventricular contractions will be highlighted...
  89. ncbi Combination treatment in hypertension: the VeraTran Study
    G Mancia
    Cattedra di Medicina Interna and Centro di Fisiologia Clinica e Ipertensionean, Ospedale S. Gerardo, Monza, Italy
    Am J Hypertens 10:153S-158S. 1997
    ..The results of the study demonstrate that the fixed combination of a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor allows one to obtain an effective and balanced blood pressure control throughout the 24 h...
  90. ncbi Current antihypertensive treatment: can we do better?
    G Mancia
    Cattedra di Clinica Medica, University of Milan Bicocca, San Gerardo Hospital, Milan, Italy
    Am J Hypertens 12:131S-138S. 1999
    ..New monotherapies that can significantly reduce blood pressure, especially SBP, and confer protection on the target organs most affected by chronic hypertension may substantially add to current treatment...
  91. ncbi 24-hour blood pressure profile in centenarians
    Giovanni Bertinieri
    Centro Interuniversitario di Fisiologia Clinica ed Ipertensione, , Ospedale S.Gerardo, Monza, Italy
    J Hypertens 20:1765-9. 2002
    ..At variance with these subjects, however, in centenarians nocturnal hypotension and bradycardia are abolished, presumably because of a derangement in the central sleep influences on the cardiovascular system...
  92. ncbi Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice
    Giuseppe Mancia
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Monza, Italy
    J Hypertens 22:2387-96. 2004
    ..Few reports are available on BP control in relation to the cardiovascular risk profile in patients followed by specialist physicians...
  93. ncbi Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population
    Giuseppe Mancia
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Italy
    J Hypertens 26:1602-11. 2008
    ..Limited or no evidence exists on whether and to what extent metabolic syndrome increases the risk of developing office hypertension, daily-life hypertension and left ventricular hypertrophy...
  94. ncbi [ESH/ESC 2007 Guidelines for the management of arterial hypertension]
    Giuseppe Mancia
    Clinica Medica, Ospedale San Gerardo, , Monza, Milano, Italia
    Rev Esp Cardiol 60:968.e1-94. 2007
  95. ncbi New-onset diabetes and antihypertensive drugs
    Giuseppe Mancia
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Università Milano, Bicocca, Italy
    J Hypertens 24:3-10. 2006
    ..This paper provides new insights into the potential mechanisms responsible for the phenomenon and the clinical significance of antihypertensive drug-induced diabetes...
  96. ncbi Protection of patients with diabetes, with or without hypertension: implications of ADVANCE for clinical practice
    Giuseppe Mancia
    Clinica Medica, Department of Medicine and Prevention, San Gerardo Hospital, University of Milan Bicocca, Monza, Milan, Italy
    J Hypertens Suppl 27:S19-23. 2009
    ....
  97. ncbi Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events
    Giuseppe Mancia
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale San Gerardo dei Tintori, Italy
    J Hypertens 28:999-1006. 2010
    ....
  98. ncbi Joint National Committee VII and European Society of Hypertension/European Society of Cardiology guidelines for evaluating and treating hypertension: a two-way road?
    Giuseppe Mancia
    Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Italy
    J Am Soc Nephrol 16:S74-7. 2005
    ..It also highlights the major agreements and disagreements between the two sets of guidelines and their implications for daily clinical practice...
  99. ncbi Long-term risk of sustained hypertension in white-coat or masked hypertension
    Giuseppe Mancia
    Clinica Medica, Ospedale S Gerardo dei Tintori, Via Pergolesi 33, 20052 Milan, Italy
    Hypertension 54:226-32. 2009
    ..Subjects with WCHT and MHT are at increased risk of developing SHT. This may contribute to their prognosis that appears to be worse as compared with that of normotensive subjects...
  100. ncbi Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population
    Giuseppe Mancia
    Istituto di Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Universita Milano Bicocca, Ospedale S Gerardo, Monza, Milan, Italy
    Hypertension 45:1072-7. 2005
    ..Thus, in the PAMELA population, glucose and lipid values are independently related to blood pressure. This is also the case when daily life blood pressure values are considered...
  101. ncbi Hypertension and the heart
    Giuseppe Mancia
    Clinica Medica, Universita Milano Bicocca, Ospedale San Gerardo, Monza, Milano, Italy
    Semin Cardiothorac Vasc Anesth 10:198-202. 2006
    ..Both phenomena have important clinic and therapeutic implications potentiating the cardiovascular risk profile of the hypertensive patient...